Fedratinib: First Approval
Hannah A. Blair
10.6084/m9.figshare.9883325.v1
https://adisjournals.figshare.com/articles/online_resource/Fedratinib_First_Approval/9883325
<p><b>Compliance with Ethical Standards</b></p>
<p><b>Funding</b> The preparation of this review was not supported by any external funding.</p>
<p><b>Conflicts of interest</b><b><i> </i></b>During the peer
review process the manufacturer of the agent under review was offered an
opportunity to comment on the article. Changes resulting from any comments
received were made by the authors on the basis of scientific completeness and
accuracy. Hannah A. Blair is a salaried employee of Adis International Ltd/Springer
Nature, is responsible for the article
content and declares no relevant conflicts of interest.</p><p><br></p><p>Additional
information about this Adis Drug Review can be found <a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews"><b>here.<br></b></a></p><p><br></p><p><b>Abstract<br></b></p><p>Fedratinib (INREBIC<sup>®</sup>)
is a JAK2-selective inhibitor that has been developed as an oral treatment for
myelofibrosis. In August 2019, fedratinib received
its first global approval in the USA for the treatment of adult patients<u> </u>with
intermediate-2 or high-risk primary or secondary (post-polycythemia vera or
post-essential thrombocythemia) myelofibrosis. Phase III clinical
development for myelofibrosis is ongoing worldwide. This article summarizes the
milestones in the development of fedratinib leading to this first approval for
myelofibrosis.<br></p><p></p><p>
<br></p><p>© Springer Nature Switzerland AG 2019<br></p><p><br></p>
2019-09-30 18:20:41
Fedratinib
Myelofibrosis
review
Adis Insight Report